Rohto PharmaceuticalROHTO PHARMACEUTICAL CO.,LTD.4527東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP

Rohto Pharmaceutical FY ending Mar 2020 results

About 61% of Rohto Pharmaceutical's sales come from Japan, with Asia and America making up much of the rest.

Out of every ¥100 of sales, about ¥12 is left as operating profit.

Where the money goes

For every ¥100 Rohto Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Mar 2020

Margin funnel (derived from reported values)Gross margin 60.6% → Operating margin 12.3% → Net margin 8.2%

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第88期(2023/04/01－2024/03/31)
ID S100TX7A2024-06-28Open
EDINET (FSA Japan)
有価証券報告書－第86期(令和3年4月1日－令和4年3月31日)
ID S100OFES2022-06-28Open
EDINET (FSA Japan)
有価証券報告書－第85期(令和2年4月1日－令和3年3月31日)
ID S100LOGZ2021-06-25Open

Extracted from XBRL: 50 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.